HA1077, a novel calcium antagonistic antivasospasm drug, increases both cerebral blood flow and glucose metabolism in conscious rats.
The effects of a novel calcium antagonistic antivasospasm drug, HA1077, on local cerebral blood flow (LCBF) and local cerebral glucose utilization (LCGU) were studied in 33 anatomically discrete regions of the brain in conscious rats, using the quantitative autoradiographic [14C]iodoantipyrine and [14C]2-deoxyglucose techniques. HA1077 was infused i.v. over a 30-min period (1 or 3 mg/kg). HA1077 significantly increased LCBF in 9 of 33 sites in rats given 1 mg/kg, and in 14 of 33 sites in rats given 3 mg/kg compared to the control group given vehicle. Significant increases in LCGU were also noted in 16 of 33 sites in rats given 3 mg/kg. HA1077 increased both cerebral blood flow and glucose metabolism in conscious rats.
Sako
K
K
Department of Neurosurgery, Asahikawa Medical College, Japan.
Tsuchiya
M
M
Yonemasu
Y
Y
Asano
T
T
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives*; D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D001921:Brain / Q000187:drug effects / Q000378:metabolism*; D002118:Calcium / Q000037:antagonists & inhibitors*; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D003243:Consciousness; D005947:Glucose / Q000378:metabolism*; D007546:Isoquinolines / Q000494:pharmacology*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D001786:Blood Glucose; D007546:Isoquinolines; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D005947:Glucose; C049347:fasudil; D002118:Calcium